Wall Street Zen Downgrades Enveric Biosciences (NASDAQ:ENVB) to Sell

Enveric Biosciences (NASDAQ:ENVB) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Enveric Biosciences in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Enveric Biosciences Price Performance

NASDAQ:ENVB opened at $1.53 on Friday. The stock has a market cap of $5.65 million, a P/E ratio of -0.07 and a beta of 1.13. The business’s 50-day moving average price is $1.44 and its two-hundred day moving average price is $2.10. Enveric Biosciences has a twelve month low of $1.25 and a twelve month high of $17.64.

Enveric Biosciences (NASDAQ:ENVB) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.76) EPS for the quarter.

Enveric Biosciences Company Profile

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.